Debate: Level of TSH at which thyroid hormone replacement should be initiated in gestation

Clicks: 10
ID: 337477
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #434 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In this debate, two clinicians discuss the merits and limitations of levothyroxine treatment for pregnant women with thyrotropin (TSH) concentrations 2.5-10 mIU/L. Recently published clinical practice guidelines have raised the treatment threshold, suggesting treatment for women with thyrotropin (TSH) ≥4.0 mIU/L and normal thyroxine concentrations only in the first trimester and recommending against treatment for women with TSH concentrations between 2.5 and 4.0 mIU/L. The evolution of these recommendations and the uncertainty regarding the overall balance of benefits and harms across the spectrum of mild thyroid dysfunction during pregnancy may lead to challenges in clinical practice, underscoring the importance of clear, practical guidance to support informed and consistent clinical decision-making. Dr. Bliddal argues that individualized levothyroxine treatment may remain reasonable in selected pregnant women with TSH concentrations of 2.5-4.0 mIU/L, and supports consideration of treatment in women with first trimester subclinical hypothyroidism and TSH concentrations between 4.0-10.0 mIU/L, emphasizing biological heterogeneity, limitations of fixed thresholds, and remaining evidence gaps. Dr. Maraka argues against routine levothyroxine treatment in these women, highlighting the uncertainty regarding clinical benefit and the potential risks of overtreatment.
Reference Key
openalex_W7224013150 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Spyridoula Maraka, Sofie Bliddal
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag438
URL
https://doi.org/10.1210/clinem/dgag438
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.